Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06389734
Other study ID # B-ER-111-470
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 2, 2023
Est. completion date February 2, 2024

Study information

Verified date April 2024
Source National Cheng Kung University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The potential effects of combining manual soft tissue release and physical exercise training on lung function, exercise capacity, and cardiac autonomic function in patients with moderate and severe chronic obstructive pulmonary disease were investigated.


Description:

Chronic obstructive pulmonary disease (COPD) commonly presents with accessory respiratory muscle tightness and weakness, affecting chest wall compliance and lung elasticity. However, traditional physical therapy interventions, including pursed-lip breathing, sputum clearance techniques, and respiratory muscle training, are often used in treatment guidelines, with few studies focusing on muscle release for the accessory respiratory muscles. Although the effects of manual therapy on lung function and chest tightness in COPD have been demonstrated, the effects of soft tissue release combined with exercise intervention on COPD, including lung function, exercise capacity, and cardiac autonomic function, remain unknown. Therefore, this study proposes a randomized controlled trial to investigate the effects of manual soft tissue release combined with exercise training on lung function, exercise capacity, and cardiac autonomic function in patients with COPD. It is expected that the results of this study will demonstrate that combining manual soft tissue release with exercise training may increase gas exchange in the lungs, reduce respiratory effort, improve co-morbidities, delay disease progression, and enhance patient quality of life and clinical intervention.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date February 2, 2024
Est. primary completion date February 2, 2024
Accepts healthy volunteers No
Gender All
Age group 30 Years to 80 Years
Eligibility Inclusion Criteria: - GOLD grade II~IV - Stable condition - No acute exacerbations in 6 weeks Exclusion Criteria: - Acute heart failure and, or arrhythmia - Pulmonary arterial hypertension - Skeletal and, or neuromuscular disorders - Chest surgery - Untreated or uncontrolled conditions - Rheumatoid conditions - Depends on oxygen supply

Study Design


Intervention

Behavioral:
Manual soft tissue release
The manual soft tissue release includes muscle energy techniques and passive stretching, targeting the anterior scalene, upper trapezius, pectoralis major, pectoralis minor, and diaphragm. Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.
Myofascial release
The myofascial release includes suboccipital muscle, anterior chest wall myofascial, and anterior neck myofascial. Three times a week for six weeks, with three rounds per session, each session having three repetitions, with a 30-second break in between, lasting 15 to 30 seconds each time.
Exercise training
The exercise training includes aerobic exercise training by treadmill. The initial intensity is set at 60% to 85% of the average speed measured during the patient's six-minute walk test (6MWT). Intensity adjustments will be made using the Modified Borg Scale (scores ranging from 4 to 7). Training duration is 30 minutes, three times a week for six weeks.

Locations

Country Name City State
Taiwan National Cheng Kung University Tainan

Sponsors (1)

Lead Sponsor Collaborator
National Cheng Kung University

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Forced expiratory volume in 1 s (FEV1) FEV1 is measured by the lung function test, and the unit presented will be in percent and liter. Change from baseline (0 week) to follow-up (12 weeks)
Primary forced vital capacity (FVC) FVC is measured by the lung function test, and the unit presented will be in percent and liter. Change from baseline (0 week) to follow-up (12 weeks)
Primary FEV1/FVC ratio FEV1/FVC ratio is measured by the lung function test, and the unit presented will be in percent. Change from baseline (0 week) to follow-up (12 weeks)
Primary expiratory reserve volume (ERV) ERV is measured by the lung function test, and the unit presented will be in liter. Change from baseline (0 week) to follow-up (12 weeks)
Primary functional residual capacity (FRC) FRC is measured by the lung functions test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary inspiratory capacity (IC) IC is measured by the lung functions test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary inspiratory reserve volume (IRV), IRV is measured by the lung functions test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary residual volume (RV) RV is measured by the lung function test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary total lung capacity (TLC) TLC is measured by the lung function test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary tidal volume (TV) TV is measured by the lung function test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Primary vital capacity (VC) VC is measured by the lung function test, and the unit presented will be in liters. Change from baseline (0 week) to follow-up (12 weeks)
Secondary Rate of perceived exertion (RPE) RPE is measured by the cardiopulmonary exercise test. This scale ranges from 0 (very light activity) to 10 (maximum effort activity). Change from baseline (0 week) to follow-up (12 weeks)
Secondary Oxygen consumption (VO2) VO2 is measured by the cardiopulmonary exercise test, and the unit presented will be in milliliters of oxygen consumed per minute (ml/min). Change from baseline (0 week) to follow-up (12 weeks)
Secondary oxygen saturation oxygen saturation is measured by the oximeter, and the unit presented will be in percent Change from baseline (0 week) to follow-up (12 weeks)
Secondary heart rate (HR) HR is measured by cardiopulmonary exercise test, and the unit presented will be in beat per minute (BPM) Change from baseline (0 week) to follow-up (12 weeks)
Secondary blood pressure (BP) BP is measured by the cardiopulmonary exercise test, which is divided into two parameters: systolic blood pressure (SBP) and diastolic blood pressure (DBP).
The unit presented will be in millimeters of mercury (mmHg).
Change from baseline (0 week) to follow-up (12 weeks)
Secondary Diaphragmatic mobility Diaphragmatic mobility is measured by the ultrasound, and the unit presented will be in millimeters Change from baseline (0 week) to follow-up (12 weeks)
Secondary Cardiac Autonomic Function Cardiac Autonomic Function is measured by heart rate variability of electrocardiography, and the unit presented will be in millisecond (ms) and millisecond square (ms2) Change from baseline (0 week) to follow-up (12 weeks)
Secondary six minute walk test (6-MWT) 6-MWT assesses the distance a person can walk within 6 minutes, and the unit presented will be in meters. Change from baseline (0 week) to follow-up (12 weeks)
Secondary maximal expiratory pressure (MEP) MEP is measured by the pressure meter, and the unit presented will be in centimetre of water (cmH2O). Change from baseline (0 week) to follow-up (12 weeks)
Secondary maximal inspiratory pressure (MIP) MIP is measured by the pressure meter, and the unit presented will be in centimetre of water (cmH2O). Change from baseline (0 week) to follow-up (12 weeks)
Secondary St. George's Respiratory Questionnaire (SGRQ) SGRQ is assessing how obstructive airway disease affects overall health, daily life, and well-being. Scores range from 0 to 100, with higher scores indicating more limitations. Change from baseline (0 week) to follow-up (12 weeks)
Secondary fatigue severity scale (FSS) FSS is assessing the impact of fatigue on a person's activity and lifestyle. There are nine items, and each item is scored from 1 to 9 (strongly disagree to strongly agree).
Higher total scores indicate more severe fatigue.
Change from baseline (0 week) to follow-up (12 weeks)
Secondary Modified Medical Research Council (mMRC) mMRC is assessing the subjective degree of breathlessness by patients during physical activity. It rates on a scale from 0 to 4, with a higher rate indicating the worst possible shortness of breath. Change from baseline (0 week) to follow-up (12 weeks)
Secondary 36-Item Short Form Health Survey (SF-36) SF-36 is assessing the subjective survey health status and quality of life. It consists of eight sections, with scores ranging from 0 to 100. Higher scores indicate better health and less disability. Change from baseline (0 week) to follow-up (12 weeks)
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy